Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous

Inclusion Criteria

• •1. Patients with chronic kidney disease stage 5 undergoing hemodialysis and receiving paricalcitol iv for more than 1 month.
• •2. Patients with a RAND 36-Item Health Survey completed 10 to 35 days before paricalcitol iv initiation
• •3. Patients with baseline parathormone ≥ 300 pg/mL
• •4. Patients willing to give their informed consent to participate in the study.
• •5. Patients should not receive vitamin D-related compounds or cinacalcet for 3 months prior to entering the study
• •6. Patients must be on steady regimen for anemia, hypertension and diabetes for the past 30 days